Ublituximab-xiiy: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

10 February 2024

  • curprev 06:1706:17, 10 February 2024‎ Kosar Doraghi talk contribs‎ 22,457 bytes +22,457‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=BRIUMVI™ (ublituximab-xiiy |aOrAn=a |drugClass=CD20-directed cytolytic antibody |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion reactions and upper respiratory..."
Retrieved from "https://www.wikidoc.org/index.php/Ublituximab-xiiy"